<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971593</url>
  </required_header>
  <id_info>
    <org_study_id>WI170964</org_study_id>
    <nct_id>NCT01971593</nct_id>
  </id_info>
  <brief_title>The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease</brief_title>
  <official_title>Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      By blocking aldosterone signaling in patients with Tetralogy of Fallot, Transposition of the
      great vessels with a prior atrial switch, and single ventricle &quot;Fontan&quot; patients, incident
      heart failure will be delayed, symptoms of heart failure ameliorated, and risk of arrhythmias
      decreased through decreases in myocardial fibrosis.

      Half of enrolled patients will complete an SF-36 quality of life questionnaire, perform a 6
      minute walk, and have blood drawn for biomarker analysis at enrollment, again after 3 months
      without therapy, after 6 months on therapy, then finally after 12 months of eplerenone
      therapy. Half of enrolled patients will have the 3 month drug free period at the end of 12
      months on therapy. Patients will be randomly assigned to drug free period up front versus at
      the conclusion of the trial period. Eplerenone will be started at a dose of 25mg and titrated
      up to 50mg at 4 weeks if tolerated. Blood will be drawn for basic metabolic panel analysis at
      enrollment, 3 months, 4 months to allow for dose titration, and at 6 and 12 months for
      monitoring.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left institution
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procollagen N-terminal Peptide 1</measure>
    <time_frame>Baseline, 6 months and 12 months from eplerenone administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Procollagen III N-Terminal Peptide</measure>
    <time_frame>Baseline, 6 months and 12 months from eplerenone administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Galectin 3</measure>
    <time_frame>Baseline, 6 months and 12 months from eplerenone administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk</measure>
    <time_frame>Baseline, 6 months, 12 months from eplerenone administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline, 6 months, 12 months from eplerenone administration</time_frame>
    <description>Rand 36-item Short Score Physical Domain Scale (SF-36) Range: 0-100, Higher scores suggest better function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Baseline, 6 months, 12 months from eplerenone administration</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Tetralogy of Fallot</condition>
  <condition>Transposition of the Great Vessels With an Arterial Switch</condition>
  <condition>Single Ventricle With a Fontan Palliation</condition>
  <arm_group>
    <arm_group_label>Eplerenone after drug free period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone before drug free period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone after drug free period</arm_group_label>
    <arm_group_label>Eplerenone before drug free period</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of tetralogy of Fallot, transposition of the great vessels with
             a systemic right ventricle, or Fontan type palliation

          -  Patient followed regularly at Washington University-affiliated institution

          -  If female, willing to use 2 forms of contraception including one barrier method during
             protocol

        Exclusion Criteria:

          -  GFR &lt;30 ml/min

          -  Potassium &gt;5.0 mmol/L

          -  Unable or unwilling to comply with study protocol

          -  Use of potassium sparing diuretics

          -  Use of an aldosterone blocker currently or previously

          -  Known intolerance of eplerenone or aldosterone blockade

          -  Pregnant, breastfeeding, or actively trying to get pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2013</study_first_posted>
  <results_first_submitted>January 25, 2018</results_first_submitted>
  <results_first_submitted_qc>April 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2018</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ari Cedars</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eplerenone After Drug Free Period</title>
          <description>Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
Eplerenone</description>
        </group>
        <group group_id="P2">
          <title>Eplerenone Before Drug Free Period</title>
          <description>Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
Eplerenone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study Group</title>
          <description>Crossover study, all patients pooled for baseline analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tetralogy of Fallot</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with Transposition of the Great Vessels with a Systemic Right Ventricle (RV)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procollagen N-terminal Peptide 1</title>
        <time_frame>Baseline, 6 months and 12 months from eplerenone administration</time_frame>
        <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Group</title>
            <description>Change from baseline at time of drug initiation</description>
          </group>
        </group_list>
        <measure>
          <title>Procollagen N-terminal Peptide 1</title>
          <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Procollagen III N-Terminal Peptide</title>
        <time_frame>Baseline, 6 months and 12 months from eplerenone administration</time_frame>
        <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Group</title>
            <description>Change from baseline at time of drug initiation</description>
          </group>
        </group_list>
        <measure>
          <title>Procollagen III N-Terminal Peptide</title>
          <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Galectin 3</title>
        <time_frame>Baseline, 6 months and 12 months from eplerenone administration</time_frame>
        <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Group</title>
            <description>Change from baseline at time of drug initiation</description>
          </group>
        </group_list>
        <measure>
          <title>Galectin 3</title>
          <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Walk</title>
        <time_frame>Baseline, 6 months, 12 months from eplerenone administration</time_frame>
        <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Group</title>
            <description>Change from baseline at time of drug initiation</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk</title>
          <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
          <units>Feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1629" spread="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1630" spread="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1680.2" spread="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Rand 36-item Short Score Physical Domain Scale (SF-36) Range: 0-100, Higher scores suggest better function</description>
        <time_frame>Baseline, 6 months, 12 months from eplerenone administration</time_frame>
        <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Group</title>
            <description>Change from baseline at time of drug initiation</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Rand 36-item Short Score Physical Domain Scale (SF-36) Range: 0-100, Higher scores suggest better function</description>
          <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="70" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="75" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="75" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Creatinine</title>
        <time_frame>Baseline, 6 months, 12 months from eplerenone administration</time_frame>
        <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Group</title>
            <description>Change from baseline at time of drug initiation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <population>Outcome analyzed only during the eplerenone period as specified in the protocol</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 12 months while on eplerenone</time_frame>
      <desc>Adverse event data only collected during the eplerenone period</desc>
      <group_list>
        <group group_id="E1">
          <title>Eplerenone Period</title>
          <description>Change from baseline at time of drug initiation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Incomplete study enrollment led to inadequate power to derive reliable conclusions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ari Cedars</name_or_title>
      <organization>UT Southwestern</organization>
      <phone>3149224788</phone>
      <email>acedars97@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

